More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval

Closing Down Jardiance’s Lead

 
• By Andrew McConaghie
  
AZ building
Farxiga has emerged as the company's star performer in its cardiovascular, renal and metabolism franchise. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip